Role and regulatory mechanism of microRNA449 in cancer

Abstract

Abstract: More than 50% microRNAs (miRNAs) are located in tumorassociated genome of amplification region or fragile site, which may also act as oncogenes or tumor suppressor gene (TSG). Recently, researches show that the expression of miR449 is lower in human gastric, lung and ovarian cancer, and may act as TSG. The abnormal expression of miR449 plays a pivotal role in carcinogenesis and progression, and elucidating its function and regulatory mechanism can provide valuable diagnostic, prognostic biomarker for cancer management.

Key words: Neoplasms, Gene regulatory networks, microRNA-449

WANG Xiao-Li, CHANG Yong-Chao, LIU Gang. Role and regulatory mechanism of microRNA449 in cancer[J]. Journal of International Oncology, 2016, 43(2): 110-.

References

［1］ Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin4 encodes small RNAs with antisense complementarity to lin14［J］. Cell, 1993, 75(5): 843854. ［2］ Noonan EJ, Place RF, Pookot D, et al. miR449a targets HDAC1 and induces growth arrest in prostate cancer［J］. Oncogene, 2009, 28(14): 17141724. DOI:10.1038/onc.2009.19. ［3］ Lizé M, Pilarski S, Dobbelstein M. E2F1inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis［J］. Cell Death Differ, 2010, 17(3): 452458. DOI:10.1038/cdd.2009.188. ［4］ Feng M, Yu Q. miR449 regulates CDKRbE2F1 through an autoregulatory feedback circuit［J］. Cell Cycle, 2010, 9(2): 213214. ［5］ Noonan EJ, Place RF, Basak S, et al. miR449a causes rbdependent cell cycle arrest and senescence in prostate cancer cells［J］. Oncotarget, 2010, 1(5): 349358. ［6］ Bou Kheir T, FutomaKazmierczak E, Jacobsen A, et al. miR449 inhibits cell proliferation and is downregulated in gastric cancer［J］. Mol Cancer, 2011, 10: 29. DOI:10.1186/147645981029. ［7］ Luo W, Huang B, Li Z, et al. MicroRNA449a is downregulated in nonsmall cell lung cancer and inhibits migration and invasion by targeting cMet［J］. PLoS One, 2013, 8(5): e64759. DOI:10.1371/journal.pone.0064759. ［8］ Jeon HS, Lee SY, Lee EJ, et al. Combining microRNA449a/b with a HDAC inhibitor has a synergistic effect on growth arrest in lung cancer［J］. Lung Cancer, 2012, 76(2): 171176. DOI:10.1016/j.lungcan.2011.10.012. ［9］ Ma LP, Li N, He XJ, et al. miR449b and miR34c on inducing downregulation of cell cyclerelated proteins and cycle arrests in SKOV3ipl cell, an ovarian cancer cell line［J］. Beijing Da Xue Xue Bao, 2011, 43(1): 129133. ［10］ Lizé M, Klimke A, Dobbelstein M. MicroRNA449 in cell fate determination［J］. Cell Cycle, 2011, 10(17): 28742882. ［11］ Tsujiura M, Ichikawa D, Komatsu S, et al. Circulating microRNAs in plasma of patients with gastric cancers［J］. Br J Cancer, 2010, 102(7): 11741179. DOI:10.1038/sj.bjc.6605608. ［12］ Lizé M, Herr C, Klimke A, et al. MicroRNA449a levels increase by several orders of magnitude during mucociliary differentiation of airway epithelia［J］. Cell Cycle, 2010, 9(22): 45794583. ［13］ Marcet B, Chevalier B, Luxardi G, et al. Control of vertebrate multiciliogenesis by miR449 through direct repression of the Delta/Notch pathway［J］. Nat Cell Biol, 2011, 13(6): 693699. DOI:10.1038/ncb2241. ［14］ Ito T, Udaka N, Yazawa T, et al. Basic helixloophelix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium［J］. Development, 2000, 127(18): 39133921. ［15］ Taichman DB, Loomes KM, Schachtner SK, et al. Notch1 and jagged1 expression by the developing pulmonary vasculature［J］. Dev Dyn, 2002, 225(2): 166175. DOI:10.1002/dvdy.10146. ［16］ Hoesel B, Bhujabal Z, Przemeck GK, et al. Combination of in silico and in situ hybridisation approaches to identify potential Dll1 associated miRNAs during mouse embryogenesis［J］. Gene Expr Patterns, 2010, 10(6): 265273. DOI:10.1016/j.gep.2010.06.002. ［17］ Liu YJ, Lin YF, Chen YF, et al. MicroRNA449a enhances radiosensitivity in CL10 lung adenocarcinoma cells［J］. PLoS One, 2013, 8(4): e62383. DOI:10.1371/journal.pone.0062383. ［18］ Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution［J］. J Oncol, 2010: 932371. DOI:10.1155/2010/932371. ［19］ Chen H, Lin YW, Mao YQ, et al. MicroRNA449a acts as a tumor suppressor in human bladder cancer through the regulation of pocket proteins［J］. Cancer Lett, 2012, 320(1): 4047. DOI:10.1016/j.canlet.2012.01.027. ［20］ Buurman R, Gürlevik E, Schffer V, et al. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA449 in hepatocellular carcinoma cells［J］. Gastroenterology, 2012, 143(3): 811820. DOI:10.1053/j.gastro.2012.05.033. ［21］ Zhang H, Feng Z, Huang R, et al. MicroRNA449 suppresses proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1［J］. Int J Oncol, 2014, 45(5): 21432152. DOI:10.3892/ijo.2014.2596. ［22］ Jang SG, Yoo CW, Park SY, et al. Low expression of miR449 in gynecologic clear cell carcinoma［J］. Int J Gynecol Cancer, 2014, 24(9): 15581563. DOI:10.1097/IGC.0000000000000267. ［23］ Jukic DM, Rao UN, Kelly L, et al. Microrna profiling analysis of differences between the melanoma of young adults and older adults［J］. J Transl Med, 2010, 8: 27. DOI:10.1186/14795876827.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.